GRI Bio presents preclinical data on GRI-0621

GRI Bio (GRI) announced the presentation of positive preclinical data demonstrating its lead program GRI-0621 has anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis. The data was presented by Marc Hertz, PhD, Chief Executive Officer of GRI Bio in the poster titled, “Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary Fibrosis,” as part of the D21 – IMMUNOLOGICAL INSIGHTS IN LUNG INFLAMMATION AND REPAIR session at the 2025 ATS International Conference held on Wednesday, May 21, 2025. “We continue believe GRI-0621 is a promising potential treatment option for IPF, an indication where there remains significant unmet need. Our growing body of pre-clinical results continue to bolster our understanding of the role of iNKT cell activity in driving pulmonary fibrosis and further support our ongoing Phase 2a study examining the safety and tolerability of GRI-0621 and its effect on various biomarkers in IPF patients. We remain encouraged by the progress made in our Phase 2a biomarker study and look forward to reporting additional data this year,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio.